3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
3
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
Rituximab
208
Cyclophosphamide
167
Etoposide
83
Prednisone
79
Vincristine
77
Doxorubicin
76
Peripheral Blood Stem Cell Transplantation
61
Filgrastim
55
Cytarabine
47
fludarabine phosphate
46
Radiotherapy
43
Lenalidomide
41
Mycophenolic Acid
40
Tacrolimus
36
Methotrexate
35
Melphalan
35
Busulfan
35
Gemcitabine
32
Carmustine
32
Cyclosporine
31
Whole-Body Irradiation
29
Ifosfamide
28
Antilymphocyte Serum
26
zanubrutinib
25
polatuzumab vedotin
25
Dexamethasone
23
Methylprednisolone
22
ibritumomab tiuxetan
20
Carboplatin
20
Oxaliplatin
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Large B-Cell, Diffuse
×
navitoclax
×
Clear all
NCT01423539
2016-11-02
NAVIGATE
Genentech, Inc.
Phase 2
Withdrawn